GTx continues phase 3 trials of Acapodene for prostate cancer following safety review

By Lisa Kerner

Erie, Pa., Jan. 19 - GTx, Inc. said will continue clinical development as planned with its two pivotal phase 3 trials of Acapodene (toremifene citrate) following a per protocol interim safety review by an independent drug safety monitoring board, which recommended that GTx continue, according to a company news release.

GTx is evaluating the use of Acapodene in an 80 mg dose for the treatment of multiple side effects of androgen deprivation therapy in men with advanced prostate cancer, and of Acapodene 20 mg dose for the prevention of prostate cancer in high-risk men.

GTx, based in Memphis, Tenn., is a biopharmaceutical company specializing in men's health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.